Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Revenue of Vor Biopharma Inc. (VOR)
Revenue in 2023 (TTM): $
According to Vor Biopharma Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vor Biopharma Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-3,492,000 | $-114,371,000 | $-117,863,000 | $-117,863,000 |
| 2022 | $ | $-8,960,000 | $-90,893,000 | $-92,094,000 | $-90,770,000 |
| 2021 | $ | $-4,451,000 | $-67,584,000 | $-68,899,000 | $-68,780,000 |
| 2020 | $ | $-1,387,000 | $-41,950,000 | $-43,337,000 | $-43,337,000 |
| 2019 | $ | $-91,000 | $-10,172,000 | $-10,839,000 | $-11,447,000 |
| 2018 | $ | $-20,000 | $-2,840,000 | $-4,152,000 | $-4,152,000 |